Weight loss tech company Allurion is targeting the Central and Eastern Europe, Middle East, and Africa (CEMA) region after it entered a sales agency agreement with Medtronic for its artificial intelligence (AI)-powered weight loss programme.

The collaboration is another step in the close relationship between the US-based company and the medical device manufacturing giant. Medtronic is currently an investor in Allurion.

The weight loss programme includes a swallowable balloon combined with AI-powered remote monitoring software, called the Allurion Virtual Care Suite.

In a statement announcing the partnership, Allurion’s co-founder and CEO Shantanu Guar said Medtronic’s distribution channels will help offer the digital platform as a standalone product to help patients undergoing bariatric surgery.

A market model by GlobalData estimates that bariatric surgery devices across the EU5 market will be worth $21.4m by 2025.

According to Allurion, the device is the world’s first gastric balloon for weight loss that does not require a procedure for insertion, helps patients feel full, while the digital platform covers the analytics side of the treatment.  

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Allurion co-founder and CEO Shantanu Guar told Medical Device Network in February: “The balloon helps you feel full, but the digital platform is keeping track of data and provides that link between patient and provider.”

“The behaviour change programme then creates a cohesive experience that allows the patient to change their lifestyle – that’s what’s unique about our platform.”

In February 2023, Allurion went public after signing a special purpose acquisition company (SPAC) deal with Compute Health.